Figure 3
Network meta-analysis and SUCRA rank of included medications for improving SFR after ESWL which the endpoint of revisit was less than or equal to 15 days. Tamsulosin, doxazosin, terazosin, nifedipine, rowatinex and control represented the outcome that was extracted and pooled from included studies within this subdivided period respectively. The forest plot (A) showed each MET treatment compared with control group or any two treatments compared with each other, and the mean difference with 95% CI of each comparison. Those mean differences greater than 1 favored the former one of the comparison, and those mean differences less than 1 favored the latter one. If the 95% CI was above or under than 1.00, the difference was statistically significant (p < 0.05). The SUCRA ranks were calculated through the standard network model and listed in order from high to low (B).
